(Reuters) -Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a ...
Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...
The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the ...
We have written about the promise of gene therapy to correct genetic disease many times. An exciting development happened ...
New Product Shortage PLUS Endorsement fills a critical coverage gap for injury-related claims arising from product ...
India’s first CAR-T gene therapy NexCAR19 revolutionises cancer treatment with affordable innovation
India has achieved a major milestone in medical science with NexCAR19, the world’s first humanised CAR-T (Chimeric Antigen Receptor T-cell) therapy, which has made gene-based cancer treatments both ...
UniQure said the U.S. Food and Drug Administration no longer agreed that clinical data for the Dutch company's gene therapy ...
In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
The FDA’s abrupt shift on UniQure’s treatment reflects an agency that, under current leadership, is as unpredictable as it's ...
AVALA Hospital and Retina Associates perform Louisiana’s first ENCELTO procedure, offering new gene therapy treatment for ...
For autologous cell and gene therapies (CGTs), the collection of patients‘ cells is the first step in the manufacture of the medicinal product.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback